Literature DB >> 12664583

Cyclooxygenase-2 in human pathological disease.

Alane Koki1, Nasir K Khan, B Mark Woerner, A J Dannenberg, Lisa Olson, Karen Seibert, Dorothy Edwards, Madorra Hardy, Peter Isakson, Jaime L Masferrer.   

Abstract

To understand the potential role of cyclooxygenase (COX) in normal and inflammatory human diseases, we characterized the expression of COX-1 and COX-2 in biopsies of osteoarthritis, atherosclerosis, and cancer. Tissues were prepared for immunohistochemistry by standard methods, and representative cases assayed via Western blot and quantitative RT-PCR. COX-2 was not detected in normal human tissues with few exceptions. Moderate to marked COX-2 was observed in the macula densa (MD) and thick ascending limb (TAL) in human fetal kidneys, but was not detected in neonatal and adult MD and TALs. Low level, constitutive COX-2 was detected in colonic epithelium, peribronchial glands, and pancreatic ductal epithelium. Low to moderate COX-2 was detected basally in the cortex, hippocampus, hypothalamus, and spinal cord, and in reproductive tissues during ovulation, implantation and labor. No COX-2 was detected in the existing vasculature in normal tissues, and was also not expressed throughout the ductus arteriosus. COX-2 was markedly induced in human tissues of osteoarthritis, atherosclerosis and cancer. COX-2 was prominently expressed in the synovium, fibrocartilage of osteophytes, and in the blood vessels in the osteoarthritic (OA) knee joint. COX-2 was also prominently detected in the macrophages/foam cells in atherosclerotic plaques, and in the endothelium overlying and immediately adjacent to the fibrofatty lesion. Moderate- to intense COX-2 expression was consistently observed in the inflammatory cells, neoplastic lesions, and blood vessels in all epithelial-derived human cancers studied. In contrast, COX-1 was relatively ubiquitously observed in both normal and pathophysiological conditions. These data collectively imply COX-2 plays an important role in mediating a variety of inflammatory diseases, and imply COX-2 inhibitors may be effective in the prevention and/or treatment of OA, heart disease, and epithelial cancers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12664583     DOI: 10.1007/978-1-4615-0193-0_28

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  36 in total

1.  Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk.

Authors:  Wen-Jia Peng; Qian He; Jin-Xia Yang; Bing-Xiang Wang; Man-Man Lu; Song Wang; Jing Wang
Journal:  Mol Biol Rep       Date:  2011-12-09       Impact factor: 2.316

2.  Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling.

Authors:  Dan A Dixon; Neal D Tolley; Kristi Bemis-Standoli; Mark L Martinez; Andrew S Weyrich; Jason D Morrow; Stephen M Prescott; Guy A Zimmerman
Journal:  J Clin Invest       Date:  2006-09-21       Impact factor: 14.808

Review 3.  Epigenetic linkage of aging, cancer and nutrition.

Authors:  Michael Daniel; Trygve O Tollefsbol
Journal:  J Exp Biol       Date:  2015-01-01       Impact factor: 3.312

Review 4.  Interacting inflammatory and growth factor signals underlie the obesity-cancer link.

Authors:  Laura M Lashinger; Nikki A Ford; Stephen D Hursting
Journal:  J Nutr       Date:  2013-11-27       Impact factor: 4.798

5.  Helicobacter pylori seroprevalence in patients with lung cancer.

Authors:  Nikiphoros Philippou; Panagiotis Koursarakos; Evgenia Anastasakou; Vasiliki Krietsepi; Stavroula Mavrea; Anastasios Roussos; Dionissia Alepopoulou; Irineos Iliopoulos
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

6.  The impact of cyclooxygenase-2 mediated inflammation on scarless fetal wound healing.

Authors:  Traci A Wilgus; Valerie K Bergdall; Kathleen L Tober; Kara J Hill; Srabani Mitra; Nicholas A Flavahan; Tatiana M Oberyszyn
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

7.  Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.

Authors:  Bryan J Schneider; Gregory P Kalemkerian; Michael J Kraut; Antoinette J Wozniak; Francis P Worden; Daryn W Smith; Wei Chen; Shirish M Gadgeel
Journal:  J Thorac Oncol       Date:  2008-12       Impact factor: 15.609

8.  NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-beta3 activation.

Authors:  Yong-Seok Oh; Nam Won Jo; Jung Woong Choi; Hyeon Soo Kim; Sang-Won Seo; Kyung-Ok Kang; Jong-Ik Hwang; Kyun Heo; Sun-Hee Kim; Yun-Hee Kim; In-Hoo Kim; Jae Ho Kim; Yoshiko Banno; Sung Ho Ryu; Pann-Ghill Suh
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

9.  Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer.

Authors:  Jordi Tauler; James L Mulshine
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

10.  Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer.

Authors:  Peter P Grimminger; Jan Stöhlmacher; Daniel Vallböhmer; Paul M Schneider; Arnulf H Hölscher; Ralf Metzger; Peter V Danenberg; Jan Brabender
Journal:  J Oncol       Date:  2009-11-22       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.